Risk assessment with gut microbiome and metabolite markers in NAFLD development

• DOI: 10.1126/scitranslmed.abk0855
• Publication Date: 2022-06-08T17:56:36Z
• Authors: Howell Leung; Xiaoxue Long; Yueqiong Ni; Lingling Qian; Emmanouil Nychas; Sara Leal Siliceo; Dennis Pohl; Kati Hanhineva; Yan Liu; Aimin Xu; Henrik B. Nielsen; Eugeni Belda; Karine Clément; Rohit Loomba; Huating Li; Weiping Jia; Gianni Panagiotou
• Keywords: Clinical Significance; Gut microbiome

A growing body of evidence suggests interplay between the gut microbiota and pathogenesis nonalcoholic fatty liver disease (NAFLD). However, role microbiome in early detection NAFLD is unclear. Prospective studies are necessary for identifying reliable, markers NAFLD. We evaluated 2487 individuals a community-based cohort who were followed up 4.6 years after initial clinical examination biospecimen sampling. Metagenomic metabolomic characterizations using stool serum samples taken at baseline performed 90 participants progressed to controls remained free follow-up visit. Cases matched gender, age, mass index (BMI) follow-up, 4-year BMI change. Machine learning models integrating microbial signatures (14 features) correctly classified (auROCs 0.72 0.80) based on their status fat accumulation follow up, outperforming other prognostic 0.58 0.60). confirmed biological relevance features by testing diagnostic ability four external case-control cohorts examined biopsy or magnetic resonance spectroscopy, from Asia, Europe, United States. Our findings raise possibility warning development.